Non-steroidal anti-inflammatory drugs: An overview of cardiovascular risks

Pharmaceuticals

Volumn 3, Issue 7, 2010, Pages 2146-2162

  Meek, Inger L ^a   van de Laar, Mart A F J ^a   Vonkeman, Harald E ^a  

^a UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Aspirin; Cardiovascular events; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; IBUPROFEN; INDOMETACIN; LANSOPRAZOLE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHOSPHOLIPASE A2; PIROXICAM; PLACEBO; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2; PROSTAGLANDIN G2; PROSTAGLANDIN H2; PROSTAGLANDIN SYNTHASE; PROTON PUMP INHIBITOR; ROFECOXIB; THROMBOXANE A2;

ABDOMINAL PAIN; BINDING AFFINITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; ENZYME INHIBITION; GASTRIC ULCER BLEEDING; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HEARTBURN; HUMAN; HYPERTENSION; LOW DRUG DOSE; NAUSEA; OSTEOARTHRITIS; PAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENT DISEASE; RENOVASCULAR HYPERTENSION; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; STOMACH EROSION; STOMACH PERFORATION; STOMACH ULCER; STROKE; THROMBOCYTE AGGREGATION;

EID: 77955674352     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3072146     Document Type: Review

References (67)

1. Von Euler, U.S. Uber Die Specifische Blutdrucksenkende Substanz Des Menschlichen Prostate- Und Samenblasensekrets. Klin. Wochenschr. 1935, 14, 1182-1183.
2. Goldblatt, M. W. Properties of Human Seminal Plasma. J. Physiol. 1935, 84, 208-218.
3. Van, D.O.R.P.; Beerthuis, R.K.; Nugteren, D.H.; Vonkeman, H. Enzymatic conversion of all-cis-polyunsaturated fatty acids into prostaglandins. Nature 1964, 203, 839-841.
4. Van, D.O.R.P.; Beerthuis, R.K.; Nugteren, D.H.; Vonkeman, H. The biosynthesis of prostaglandins. Biochim. Biophys. Acta 1964, 90, 204-207.
5. Fu, J. Y.; Masferrer, J. L.; Seibert, K.; Raz, A.; Needleman, P. The Induction and Suppression of Prostaglandin H2 Synthase (Cyclooxygenase) in Human Monocytes. J. Biol. Chem. 1990, 265, 16737-16740.
6. Picot, D.; Loll, P. J.; Garavito, R. M. The X-Ray Crystal Structure of the Membrane Protein Prostaglandin H2 Synthase-1. Nature 1994, 367, 243-249.
7. Luong, C.; Miller, A.; Barnett, J.; Chow, J.; Ramesha, C.; Browner, M. F. Flexibility of the NSAID Binding Site in the Structure of Human Cyclooxygenase-2. Nat. Struct. Biol. 1996, 3, 927-933
8. Smith, J. B.; Willis, A. L. Aspirin Selectively Inhibits Prostaglandin Production in Human Platelets. Nat. New Biol. 1971, 231, 235-237.
9. Collier, J. G.; Flower, R. J. Effect of Aspirin on Human Seminal Prostaglandins. Lancet 1971, 2, 852-853.
10. Vonkeman, H. E.; van de Laar, M. A. Nonsteroidal Anti-Inflammatory Drugs: Adverse Effects and Their Prevention. Semin. Arthritis Rheum. 2010, 39, 294-312.
11. Catella-Lawson, F.; Crofford, L. J. Cyclooxygenase Inhibition and Thrombogenicity. Am. J. Med. 2001, 110 (Suppl. 3A), 28-32.
12. Baigent, C.; Blackwell, L.; Collins, R.; Emberson, J.; Godwin, J.; Peto, R.; Buring, J.; Hennekens, C.; Kearney, P.; Meade, T.; Patrono, C.; Roncaglioni, M. C.; Zanchetti, A. Aspirin in the Primary and Secondary Prevention of Vascular Disease: Collaborative Meta-Analysis of Individual Participant Data From Randomised Trials. Lancet 2009, 373, 1849-1860.
13. McQuaid, K. R.; Laine, L. Systematic Review and Meta-Analysis of Adverse Events of Low-Dose Aspirin and Clopidogrel in Randomized Controlled Trials. Am. J. Med. 2006, 119, 624-638.
14. Lanza, F. L. A Guideline for the Treatment and Prevention of NSAID-Induced Ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am. J. Gastroenterol. 1998, 93, 2037-2046.
15. Singh, G.; Rosen, R. D. NSAID Induced Gastrointestinal Complications: the ARAMIS Perspective--1997. Arthritis, Rheumatism, and Aging Medical Information System. J. Rheumatol. Suppl 1998, 51, 8-16.
16. Silverstein, F. E.; Graham, D. Y.; Senior, J. R.; Davies, H. W.; Struthers, B. J.; Bittman, R. M.; Geis, G. S. Misoprostol Reduces Serious Gastrointestinal Complications in Patients With Rheumatoid Arthritis Receiving Nonsteroidal Anti-Inflammatory Drugs. A Randomized, Double-Blind, Placebo-Controlled Trial. Ann. Intern. Med. 1995, 123, 241-249.
17. Lai, K. C.; Lam, S. K.; Chu, K. M.; Wong, B. C.; Hui, W. M.; Hu, W. H.; Lau, G. K.; Wong, W. M.; Yuen, M. F.; Chan, A. O.; Lai, C. L.; Wong, J. Lansoprazole for the Prevention of Recurrences of Ulcer Complications From Long-Term Low-Dose Aspirin Use. N. Engl. J. Med. 2002, 346, 2033-2038.
18. Chan, F. K.; Chung, S. C.; Suen, B. Y.; Lee, Y. T.; Leung, W. K.; Leung, V. K.; Wu, J. C.; Lau, J. Y.; Hui, Y.; Lai, M. S.; Chan, H. L.; Sung, J. J. Preventing Recurrent Upper Gastrointestinal Bleeding in Patients With Helicobacter Pylori Infection Who Are Taking Low-Dose Aspirin or Naproxen. N. Engl. J. Med. 2001, 344, 967-973.
19. Adams, S. S. The Discovery of Brufen. Chem. Br. 1987, 23, 1193-1195.
20. Jasani, M. K.; Downie, W. W.; Samuels, B. M.; Buchanan, W. W. Ibuprofen in Rheumatoid Arthritis. Clinical Study of Analgesic and Anti-Inflammatory Activity. Ann. Rheum. Dis. 1968, 27, 457-462.
21. Flower, R.; Gryglewski, R.; Herbaczynska-Cedro, K.; Vane, J. R. Effects of Anti-Inflammatory Drugs on Prostaglandin Biosynthesis. Nat. New Biol. 1972, 238, 104-106.
22. Van, H. A.; Schwartz, J. I.; Depre, M.; De, L., I; Dallob, A.; Tanaka, W.; Wynants, K.; Buntinx, A.; Arnout, J.; Wong, P. H.; Ebel, D. L.; Gertz, B. J.; De Schepper, P. J. Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX-2 Versus COX-1 in Healthy Volunteers. J. Clin. Pharmacol. 2000, 40, 1109-1120
23. Hawkey, C. J. COX-2 Inhibitors. Lancet 1999, 353, 307-314.
24. Lanzo, C. A.; Beechem, J. M.; Talley, J.; Marnett, L. J. Investigation of the Binding of Isoform-Selective Inhibitors to Prostaglandin Endoperoxide Synthases Using Fluorescence Spectroscopy. Biochemistry 1998, 37, 217-226.
25. Brun, J.; Jones, R. Nonsteroidal Anti-Inflammatory Drug-Associated Dyspepsia: the Scale of the Problem. Am. J. Med. 2001, 110, 12-13.
26. Langman, M. J.; Weil, J.; Wainwright, P.; Lawson, D. H.; Rawlins, M. D.; Logan, R. F.; Murphy, M.; Vessey, M. P.; Colin-Jones, D. G. Risks of Bleeding Peptic Ulcer Associated With Individual Non-Steroidal Anti-Inflammatory Drugs. Lancet 1994, 343, 1075-1078.
27. Vonkeman, H. E.; Fernandes, R. W.; van de Laar, M. A. Under-Utilization of Gastroprotective Drugs in Patients With NSAID-Related Ulcers. Int. J. Clin. Pharmacol. Ther. 2007, 45, 281-288.
28. Armstrong, C. P.; Blower, A. L. Non-Steroidal Anti-Inflammatory Drugs and Life Threatening Complications of Peptic Ulceration. Gut 1987, 28, 527-532.
29. Rostom, A.; Dube, C.; Wells, G.; Tugwell, P.; Welch, V.; Jolicoeur, E.; McGowan, J. Prevention of NSAID-Induced Gastroduodenal Ulcers. Cochrane. Database. Syst. Rev. 2002, CD002296.
30. Graham, D. Y.; Agrawal, N. M.; Campbell, D. R.; Haber, M. M.; Collis, C.; Lukasik, N. L.; Huang, B. Ulcer Prevention in Long-Term Users of Nonsteroidal Anti-Inflammatory Drugs: Results of a Double-Blind, Randomized, Multicenter, Active- and Placebo-Controlled Study of Misoprostol Vs Lansoprazole. Arch. Intern. Med. 2002, 162, 169-175.
31. Bianchi, P. G.; Lazzaroni, M.; Imbesi, V.; Montrone, F.; Santagada, T. Efficacy of Pantoprazole in the Prevention of Peptic Ulcers, Induced by Non-Steroidal Anti-Inflammatory Drugs: a Prospective, Placebo-Controlled, Double-Blind, Parallel-Group Study. Dig. Liver Dis. 2000, 32, 201-208.
32. Koch, M.; Dezi, A.; Ferrario, F.; Capurso, I. Prevention of Nonsteroidal Anti-Inflammatory Drug-Induced Gastrointestinal Mucosal Injury. A Meta-Analysis of Randomized Controlled Clinical Trials. Arch. Intern. Med. 1996, 156, 2321-2332.
33. Taha, A. S.; Hudson, N.; Hawkey, C. J.; Swannell, A. J.; Trye, P. N.; Cottrell, J.; Mann, S. G.; Simon, T. J.; Sturrock, R. D.; Russell, R. I. Famotidine for the Prevention of Gastric and Duodenal Ulcers Caused by Nonsteroidal Antiinflammatory Drugs. N. Engl. J. Med. 1996, 334, 1435-1439.
34. Chan, F. K.; To, K. F.; Wu, J. C.; Yung, M. Y.; Leung, W. K.; Kwok, T.; Hui, Y.; Chan, H. L.; Chan, C. S.; Hui, E.; Woo, J.; Sung, J. J. Eradication of Helicobacter Pylori and Risk of Peptic Ulcers in Patients Starting Long-Term Treatment With Non-Steroidal Anti-Inflammatory Drugs: a Randomised Trial. Lancet 2002, 359, 9-13.
35. Chan, F. K.; Sung, J. J.; Chung, S. C.; To, K. F.; Yung, M. Y.; Leung, V. K.; Lee, Y. T.; Chan, C. S.; Li, E. K.; Woo, J. Randomised Trial of Eradication of Helicobacter Pylori Before Non-Steroidal Anti-Inflammatory Drug Therapy to Prevent Peptic Ulcers. Lancet 1997, 350, 975-979.
36. Fitzgerald, G. A. Cardiovascular Pharmacology of Nonselective Nonsteroidal Anti-Inflammatory Drugs and Coxibs: Clinical Considerations. Am. J. Cardiol. 2002, 89, 26-32.
37. Vonkeman, H. E.; Brouwers, J. R.; van de Laar, M. A. Understanding the NSAID Related Risk of Vascular Events. BMJ 2006, 332, 895-898.
38. Bresalier, R. S.; Sandler, R. S.; Quan, H.; Bolognese, J. A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Konstam, M. A.; Baron, J. A. Cardiovascular Events Associated With Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. N. Engl. J. Med. 2005, 352, 1092-1102.
39. Kearney, P. M.; Baigent, C.; Godwin, J.; Halls, H.; Emberson, J. R.; Patrono, C. Do Selective Cyclo-Oxygenase-2 Inhibitors and Traditional Non-Steroidal Anti-Inflammatory Drugs Increase the Risk of Atherothrombosis? Meta-Analysis of Randomised Trials. BMJ 2006, 332, 1302-1308.
40. McGettigan, P.; Henry, D. Cardiovascular Risk and Inhibition of Cyclooxygenase: a Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2. JAMA 2006, 296, 1633-1644.
41. Scott, P. A.; Kingsley, G. H.; Smith, C. M.; Choy, E. H.; Scott, D. L. Non-Steroidal Anti-Inflammatory Drugs and Myocardial Infarctions: Comparative Systematic Review of Evidence From Observational Studies and Randomised Controlled Trials. Ann. Rheum. Dis. 2007, 66, 1296-1304.
42. Solomon, S. D.; Wittes, J.; Finn, P. V.; Fowler, R.; Viner, J.; Bertagnolli, M. M.; Arber, N.; Levin, B.; Meinert, C. L.; Martin, B.; Pater, J. L.; Goss, P. E.; Lance, P.; Obara, S.; Chew, E. Y.; Kim, J.; Arndt, G.; Hawk, E. Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: the Cross Trial Safety Analysis. Circulation 2008, 117, 2104-2113.
43. Garcia Rodriguez, L. A.; Tacconelli, S.; Patrignani, P. Role of Dose Potency in the Prediction of Risk of Myocardial Infarction Associated With Nonsteroidal Anti-Inflammatory Drugs in the General Population. J. Am. Coll. Cardiol. 2008, 52, 1628-1636.
44. Gislason, G. H.; Jacobsen, S.; Rasmussen, J. N.; Rasmussen, S.; Buch, P.; Friberg, J.; Schramm, T. K.; Abildstrom, S. Z.; Kober, L.; Madsen, M.; Torp-Pedersen, C. Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction. Circulation 2006, 113, 2906-2913.
45. Fosbol, E. L.; Gislason, G. H.; Jacobsen, S.; Folke, F.; Hansen, M. L.; Schramm, T. K.; Sorensen, R.; Rasmussen, J. N.; Andersen, S. S.; Abildstrom, S. Z.; Traerup, J.; Poulsen, H. E.; Rasmussen, S.; Kober, L.; Torp-Pedersen, C. Risk of Myocardial Infarction and Death Associated With the Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Among Healthy Individuals: a Nationwide Cohort Study. Clin. Pharmacol. Ther. 2009, 85, 190-197.
46. FDA Public Health Advisory: Alert for Healthcare Professionals Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Available online: http://www.fda.gov/Drugs/DrugSafety/ (accessed on 7 July 2010).
47. European Medicines Agency update on review of non-selective NSAIDs. Available online: http://www.ema.europa.eu/htms/human/drugalert/drugalert.htm (accessed on 7 July 2010).
48. Chan, F. K. Primer: Managing NSAID-Induced Ulcer Complications--Balancing Gastrointestinal and Cardiovascular Risks. Nat. Clin. Pract. Gastroenterol. Hepatol. 2006, 3, 563-573.
49. Bhatt, D. L.; Scheiman, J.; Abraham, N. S.; Antman, E. M.; Chan, F. K.; Furberg, C. D.; Johnson, D. A.; Mahaffey, K. W.; Quigley, E. M. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: a Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008, 118, 1894-1909.
50. Antman, E. M.; Bennett, J. S.; Daugherty, A.; Furberg, C.; Roberts, H.; Taubert, K. A. Use of Nonsteroidal Antiinflammatory Drugs: an Update for Clinicians: a Scientific Statement From the American Heart Association. Circulation 2007, 115, 1634-1642.
51. Solomon, D. Nonselective NSAIDs: cardiovascular effects. UpToDate, Available onlin: http://www.uptodate.com/ (accessed on 30 June 2010).
52. Aw, T. J.; Haas, S. J.; Liew, D.; Krum, H. Meta-Analysis of Cyclooxygenase-2 Inhibitors and Their Effects on Blood Pressure. Arch. Intern. Med. 2005, 165, 490-496.
53. Rose, B. D.; Post, T. W. NSAIDs: Acute renal failure and nephrotic syndrome. UpToDate Available onlin: http://www.uptodate.com/ (accessed on 30 June 2010).
54. Feenstra, J.; Heerdink, E. R.; Grobbee, D. E.; Stricker, B. H. Association of Nonsteroidal Anti-Inflammatory Drugs With First Occurrence of Heart Failure and With Relapsing Heart Failure: the Rotterdam Study. Arch. Intern. Med. 2002, 162, 265-270.
55. Page, J.; Henry, D. Consumption of NSAIDs and the Development of Congestive Heart Failure in Elderly Patients: an Underrecognized Public Health Problem. Arch. Intern. Med. 2000, 160, 777-784.
56. Gislason, G. H.; Rasmussen, J. N.; Abildstrom, S. Z.; Schramm, T. K.; Hansen, M. L.; Fosbol, E. L.; Sorensen, R.; Folke, F.; Buch, P.; Gadsboll, N.; Rasmussen, S.; Poulsen, H. E.; Kober, L.; Madsen, M.; Torp-Pedersen, C. Increased Mortality and Cardiovascular Morbidity Associated With Use of Nonsteroidal Anti-Inflammatory Drugs in Chronic Heart Failure. Arch. Intern. Med. 2009, 169, 141-149.
57. Chan, C. C.; Reid, C. M.; Aw, T. J.; Liew, D.; Haas, S. J.; Krum, H. Do COX-2 Inhibitors Raise Blood Pressure More Than Nonselective NSAIDs and Placebo? An Updated Meta-Analysis. J. Hypertens. 2009, 27, 2332-2341.
58. Swan, S. K.; Rudy, D. W.; Lasseter, K. C.; Ryan, C. F.; Buechel, K. L.; Lambrecht, L. J.; Pinto, M. B.; Dilzer, S. C.; Obrda, O.; Sundblad, K. J.; Gumbs, C. P.; Ebel, D. L.; Quan, H.; Larson, P. J.; Schwartz, J. I.; Musliner, T. A.; Gertz, B. J.; Brater, D. C.; Yao, S. L. Effect of Cyclooxygenase-2 Inhibition on Renal Function in Elderly Persons Receiving a Low-Salt Diet. A Randomized, Controlled Trial. Ann. Intern. Med. 2000, 133, 1-9.
59. Schneider, V.; Levesque, L. E.; Zhang, B.; Hutchinson, T.; Brophy, J. M. Association of Selective and Conventional Nonsteroidal Antiinflammatory Drugs with Acute Renal Failure: A Population-Based, Nested Case-Control Analysis. Am. J. Epidemiol. 2006, 164, 881-889.
60. Clive, D. M.; Stoff, J. S. Renal Syndromes Associated With Nonsteroidal Antiinflammatory Drugs. N. Engl. J. Med. 1984, 310, 563-572.
61. Wallace, J. L.; Viappiani, S.; Bolla, M. Cyclooxygenase-Inhibiting Nitric Oxide Donators for Osteoarthritis. Trends Pharmacol. Sci. 2009, 30, 112-117.
62. White, W. B.; Schnitzer, T. J.; Fleming, R.; Duquesroix, B.; Beekman, M. Effects of the Cyclooxygenase Inhibiting Nitric Oxide Donator Naproxcinod Versus Naproxen on Systemic Blood Pressure in Patients With Osteoarthritis. Am. J. Cardiol. 2009, 104, 840-845.
63. Catella-Lawson, F.; Reilly, M. P.; Kapoor, S. C.; Cucchiara, A. J.; DeMarco, S.; Tournier, B.; Vyas, S. N.; Fitzgerald, G. A. Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin. N. Engl. J. Med. 2001, 345, 1809-1817.
64. Capone, M. L.; Sciulli, M. G.; Tacconelli, S.; Grana, M.; Ricciotti, E.; Renda, G.; Di, G. P.; Merciaro, G.; Patrignani, P. Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects. J. Am Coll. Cardiol. 2005, 45, 1295-1301.
65. Patrono, C.; Garcia Rodriguez, L. A.; Landolfi, R.; Baigent, C. Low-Dose Aspirin for the Prevention of Atherothrombosis. N. Engl. J. Med. 2005, 353, 2373-2383.
66. Fitzgerald, G. A. Parsing an Enigma: the Pharmacodynamics of Aspirin Resistance. Lancet 2003, 361, 542-544.
67. Richardson, C. G.; Chalmers, A.; Llewellyn-Thomas, H. A.; Klinkhoff, A.; Carswell, A.; Kopec, J. A. Pain Relief in Osteoarthritis: Patients' Willingness to Risk Medication-Induced Gastrointestinal, Cardiovascular, and Cerebrovascular Complications. J. Rheumatol. 2007, 34, 1569-1575.